151282 20251017144611.0 doi 10.1016/j.drup.2021.100753 sideral 124124 ART-2021-124124 eng Stankovic, T. In vitro biomimetic models for glioblastoma-a promising tool for drug response studies 2021 Access copy available to the general public Unrestricted The poor response of glioblastoma to current treatment protocols is a consequence of its intrinsic drug resistance. Resistance to chemotherapy is primarily associated with considerable cellular heterogeneity, and plasticity of glioblastoma cells, alterations in gene expression, presence of specific tumor microenvironment conditions and blood-brain barrier. In an attempt to successfully overcome chemoresistance and better understand the biological behavior of glioblastoma, numerous tri-dimensional (3D) biomimetic models were developed in the past decade. These novel advanced models are able to better recapitulate the spatial organization of glioblastoma in a real time, therefore providing more realistic and reliable evidence to the response of glioblastoma to therapy. Moreover, these models enable the fine-tuning of different tumor microenvironment conditions and facilitate studies on the effects of the tumor microenvironment on glioblastoma chemoresistance. This review outlines current knowledge on the essence of glioblastoma chemoresistance and describes the progress achieved by 3D biomimetic models. Moreover, comprehensive literature assessment regarding the influence of 3D culturing and microenvironment mimicking on glioblastoma gene expression and biological behavior is also provided. The contribution of the blood-brain barrier as well as the blood-tumor barrier to glioblastoma chemoresistance is also reviewed from the perspective of 3D biomimetic models. Finally, the role of mathematical models in predicting 3D glioblastoma behavior and drug response is elaborated. In the future, technological innovations along with mathematical simulations should create reliable 3D biomimetic systems for glioblastoma research that should facilitate the identification and possibly application in preclinical drug testing and precision medicine. info:eu-repo/grantAgreement/EC/H2020/829010/EU/Advanced and versatile PRInting platform for the next generation of active Microfluidic dEvices/PRIME This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 829010-PRIME info:eu-repo/grantAgreement/ES/ISCIII/PFIS/IF16-00050 info:eu-repo/grantAgreement/ES/MICINN/PID2019-110895RB-I00 info:eu-repo/semantics/openAccess by-nc-nd https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es 22.841 2021 PHARMACOLOGY & PHARMACY 2 / 279 = 0.007 2021 Q1 T1 3.845 2021 Cancer Research 2021 Q1 Pharmacology (medical) 2021 Q1 Pharmacology 2021 Q1 Infectious Diseases 2021 Q1 30.8 2021 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Randelovic, T. (orcid)0000-0001-7232-7588 Dragoj, M. Stojkovic Buric, S. Fernández, L. Universidad de Zaragoza (orcid)0000-0001-5376-4440 Ochoa, I. Universidad de Zaragoza (orcid)0000-0003-2410-5678 Pérez-García, V.M. Pešic, M. 1003 443 Universidad de Zaragoza Dpto. Anatom.Histolog.Humanas Area Histología 5004 605 Universidad de Zaragoza Dpto. Ingeniería Mecánica Área Mec.Med.Cont. y Teor.Est. 55 (2021), 100753 [24 pp.] Drug resist. updat. DRUG RESISTANCE UPDATES 1368-7646 2188397 http://zaguan.unizar.es/record/151282/files/texto_completo.pdf Versión publicada 2428292 http://zaguan.unizar.es/record/151282/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:151282 articulos driver 2025-10-17-14:17:20 ARTICLE